Your session is about to expire
← Back to Search
Botanical-based drug
NBT-NM108 for Coronavirus (COVGUT20 Trial)
Phase 2
Waitlist Available
Led By Asa Oxner, MD
Research Sponsored by Notitia Biotechnologies Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at days 0, 14, 28, and 56
Awards & highlights
Summary
This trial is testing a new plant-based drug called NBT-NM108. It aims to help early-stage COVID-19 patients by changing the balance of bacteria in their gut. The goal is to see if this can improve their symptoms and recovery.
Eligible Conditions
- Coronavirus
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at days 0, 14, 28, and 56
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at days 0, 14, 28, and 56
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Outcome of COVID-19 related illnesses
Proportion of participants who have complete resolution of all objective symptoms
Proportion of participants who have complete resolution of subjective symptoms
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: NBT-NM108 + Usual CareExperimental Treatment1 Intervention
Group II: Usual Care OnlyActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NBT-NM108
2023
Completed Phase 2
~60
Find a Location
Who is running the clinical trial?
Notitia Biotechnologies CompanyLead Sponsor
University of South FloridaOTHER
422 Previous Clinical Trials
189,183 Total Patients Enrolled
Rutgers UniversityOTHER
115 Previous Clinical Trials
2,804,191 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger